First Opinion By Laura E. Riley and Brenna L. Hughes Pregnant and lactating women should not be excluded from Covid-19 drug, vaccine trials
Politics By Lev Facher and Nicholas Florko Trump promises seniors $200 prescription drug gift certificates, but questions abound
First Opinion By Luciana Borio and Jesse L. Goodman A vaccine alone won’t stop Covid-19. We also need a trusted plan for it
Politics By Nicholas Florko and Lev Facher Trump’s last-ditch drug pricing moves could help him in November. But they likely won’t save Americans money
Politics By Nicholas Florko With election looming, Trump releases major, last-ditch drug pricing order
Politics By Lev Facher A Senate race in Kansas between two doctors sets the stage for an election hyper-focused on health policy — and on Covid-19
First Opinion By Josephine Johnston The U.S. must do some heavy lifting to prepare for heritable genome editing
Politics By Nicholas Florko How Trump could use a rare regulatory maneuver to lower drug prices before Election Day, and how it could backfire
First Opinion By Stephen Patrick The lack of a national policy agenda for children during Covid-19 — and beyond — causes grave harm
Politics By Nicholas Florko New poll shows wide support for several Trump drug pricing reforms, but not rebate changes
Health By Lev Facher Trump pledges a Covid-19 vaccine by end of 2020 — without acknowledging the scientific uncertainty
Politics By Nicholas Florko Drug industry lobbyists circulate two drug pricing proposals in hopes of warding off a Trump executive order
Politics By Nicholas Florko and Lev Facher As Covid-19 pressures mount, political newcomer Stephen Hahn struggles to protect an FDA under siege
Exclusive By Nicholas Florko and Lev Facher PhRMA scrambles to respond to Trump’s drug pricing ultimatum, as Monday deadline looms
Politics By Lev Facher ‘No miracle is coming’: In acceptance speech, Biden rips Trump for Covid-19 mismanagement
Pharmalot By Ed Silverman Drug makers seek to curtail discounts paid to hospitals as part of a controversial federal program
Politics By Juliet Isselbacher ‘A powerful shift’: Disability advocacy, once an afterthought in presidential races, gains new traction
STAT+ Conversations By Rick Berke, Erin Mershon, and Lev Facher STAT+ Conversations: How pharma is influencing the 2020 election
Politics By Nicholas Florko Trump orders government to buy certain drugs solely from U.S. factories, setting up major shakeup for industry
Politics By Amy Sokolow Scientists are testing pricey rare-disease drugs as Covid-19 treatments. What if one works?
Politics By Nicholas Florko and Lev Facher The drug industry’s new tactic in Washington: calling Trump’s bluff
Pharmalot By Ed Silverman Seeking to battle high drug prices and the opioid crisis, two states ponder banning gifts to doctors
Politics By Nicholas Florko and Lev Facher Trump administration unveils executive orders to curb drug prices — but they come with caveats
Health Tech By Natalya Ortolano ‘X to the Z’: San Francisco official pushes city to condemn public hospital’s Zuckerberg name
Politics By Nicholas Florko The FDA got a lot more flexible during Covid — and pharma’s already pushing to make it permanent
Health Tech By Rebecca Robbins Health tech companies are shelling out more to lobby Washington during the pandemic